← All IPOs

Symbiotec Pharmalab IPO Shareholding Pattern

MainboardListed
SYMBIOTEC · · NSE

Updated · GMP, subscription and listing data refresh through the day.

Symbiotec Pharmalab IPO Details

RegistrarMUFG Intime India Private Limited (Formerly Link Intime India Private Limited)
Lead managersJM Financial Limited
Offer documentDraft (DRHP)
Fresh issue₹150 Cr
Offer for sale₹1,607 Cr

Symbiotec Pharmalab Financials ₹ in crore

Revenue CAGR+10.2%2024 → 2026 · 2 yrs
Profit CAGR+4.8%2024 → 2026 · 2 yrs
Total assets CAGR+17.3%2024 → 2026 · 2 yrs
00%2505%50010%75015%100020%202420252026
₹ crore202420252026
Revenue₹716.25₹751.55₹869.15
Expenses———
Net profit (PAT)₹100.06₹96.79₹109.9
PAT margin14.0%12.9%12.6%
Total assets₹1,294.79₹1,579.65₹1,780.79

Symbiotec Pharmalab Shareholding before & after the IPO

Before the IPO
Pre-issue · RHP capital structure
34.47%
Promoter
After the IPO
Post-issue

This issue’s prospectus doesn’t state the post-issue register, and the exchange pattern is only filed around listing.

Promoter & promoter groupbefore the IPO
Holding34.47%
Shares2,16,33,968

The founding owners and their group entities.

Pre-issue register from the RHP capital structure, cross-checked against exchange data. Pre-issue percentages are taken from the disclosure, never estimated.

Symbiotec Pharmalab IPO Lot Size & Minimum Investment by investor category

ApplicationSharesAmount at ₹988
Retail (min)1 lot15₹14,820
Retail (max)13 lots195₹1,92,660
sHNI (min)14 lots210₹2,07,480
bHNI (min)68 lots1,020₹10,07,760

One lot is 15 shares, so a single application at the ₹988 cut-off costs ₹14,820. Retail applications are capped at ₹2,00,000, which is 13 lots for this issue. Amounts are shown at the upper band because applications are made at the cut-off price.

Symbiotec Pharmalab IPO Strengths & Risks as disclosed in the DRHP

Strengths and risk factors from this issue’s prospectus aren’t available yet.

How to check Symbiotec Pharmalab IPO allotment status

Allotment is decided and published by the issue’s registrar, not by the exchange and not by alphave. For Symbiotec Pharmalab Limited, the registrar is MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) — allotment is finalised in the days between the issue closing on 27 Aug 2026 and listing on 01 Sept 2026.

RegistrarMUFG Intime India Private Limited (Formerly Link Intime India Private Limited)
You will needPAN, application number or demat ID
Issue closes27 Aug 2026
Listing date01 Sept 2026
Issue opens
Mon, 24 Aug, 2026
Bidding 10:00 am – 5:00 pm IST
Issue closes
Thu, 27 Aug, 2026
Last day to bid · UPI mandate by 5:00 pm
Allotment finalisedTentative
Fri, 28 Aug, 2026
By MUFG Intime India Private Limited (Formerly Link Intime India Private Limited); check with PAN, application no. or DP ID
Refunds & UPI unblockTentative
Mon, 31 Aug, 2026
Unallotted amounts released · allotted shares credited to demat
Listing
Tue, 01 Sept, 2026
NSE · trading from 10:00 am IST

Allotment and refund dates follow SEBI’s T+3 listing timeline in trading days and are tentative until the registrar and the exchange confirm them. alphave does not hold allotment results — only the registrar can show whether an application was allotted.

The registrar publishes allotment on its own portal: MUFG Intime. Your bank will also show the blocked amount released if shares were not allotted.

Symbiotec Pharmalab IPO Shareholding Pattern FAQs

What is the pre-IPO shareholding of Symbiotec Pharmalab?

Before the issue the promoter and promoter group hold 34.47% of Symbiotec Pharmalab Limited. An unlisted company has no public shareholders; the public holding is created by the shares sold in this IPO.

Where does the shareholding pattern come from?

The pre-issue register is the capital structure disclosed in the offer document; the post-issue pattern is the company's shareholding-pattern filing with NSE or BSE once it is published, and the offer document's disclosed post-issue register until then.

Symbiotec Pharmalab IPO Registrar where allotment and refund queries go

RegistrarMUFG Intime India Private Limited (Formerly Link Intime India Private Limited)

The registrar processes the allotment and the refunds. Contact details are as printed in the offer document; the exchange and your broker cannot change an allotment.

How to Apply for the Symbiotec Pharmalab IPO ASBA and UPI, as SEBI sets them

  1. Apply through your broker’s IPO window or your bank’s net banking (ASBA). The money stays in your own account and is only blocked until allotment.
  2. Choose the number of lots and bid at the cut-off price. Retail applications are capped at ₹2,00,000; above that the bid moves to the non-institutional category.
  3. If you applied through a broker, approve the UPI mandate in your payment app. The mandate must be approved by 5 pm on the day after your bid, and by 5 pm on the closing day for bids made on the last day (27 Aug 2026).
  4. One application per PAN. A second application under the same PAN is rejected, and both may be.
  5. After allotment the blocked amount is released for shares not allotted. Allotment and refund queries go to the registrar, MUFG Intime India Private Limited (Formerly Link Intime India Private Limited), not to the exchange or the broker.

What is GMP in an IPO?

Grey Market Premium is the price at which an unlisted IPO application or share changes hands informally, before the stock is listed on the exchange. It is quoted as a rupee figure over the issue price: a premium of ₹185 on a ₹988 upper band means the grey market is dealing at ₹1,173.

The grey market is an over-the-counter market between private dealers. It is not operated or supervised by NSE, BSE or SEBI, no trade is settled through a clearing corporation, and no dealer is obliged to publish or honour a quote. Figures are collected by third-party reporters and different sources routinely disagree, which is why a premium can move sharply within a day or vanish entirely once bidding closes.

Grey Market Premium is an unofficial, unregulated over-the-counter datapoint reported by third parties. It is not a price, a forecast, or an indication of listing gains, and is not investment advice.